All In Biotech

Drug Trial Radar · NCT07556107

The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)

A Randomized Controlled Trial Comparing Renal Effects of Vancomycin Combined With Either Piperacillin/Tazobactam or Meropenem: VPT Patient Safety (VPS) Study

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 852 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

852

Planned (sponsor's estimate)

Start

Aug 17, 2026

Primary completion

Jun 30, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Bassett HealthcareAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Johns Hopkins University; Patient-Centered Outcomes Research Institute
First posted
Apr 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The VPT Safety Trial (VPS) compares two common antibiotic combinations to see how they affect the kidneys of patients in the hospital with serious infections. Both combinations are approved by the Food and Drug Administration (FDA). The goal is to help doctors know which combination is safer so they can make better choices for their patients.

Conditions

  • Infection
  • Acute Kidney Injury
  • Sepsis

Interventions

  • Piperacillin + TazobactamDrug

    PT Dosing (concealed): PT dosing is standard irrespective of infection severity. 4.5 gm IV loading dose over 30 min, then 4.5 g IV over 4 hr (extended infusion) 6 hrs after the loading dose, and then q 8 hr

  • meropenemDrug

    M dosing (concealed): M dosing depends on infection severity. 1 gm loading IV dose over 30 min, then 1 gm IV over 4 hr (extended infusion) q 8 hr (default dosing). Clinician has option to increase to 2 gm IV q 8 hr for severe infections and to decrease back to default dosing if previously chosen higher dosing is no longer deemed indicated.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Serum cystatin C (Scys)Time frame: 7 days

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • University of Massachusetts Chan Medical School

    Worcester, Massachusetts · Not yet recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • Bassett Medical Center

    Cooperstown, New York · Recruiting

  • NY Presbyterian/Queens

    Flushing, New York · Not yet recruiting

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina · Recruiting

  • Medical University of South Carolina - South Carolina Clinical & Translational Research Institute

    Charleston, South Carolina · Recruiting

  • West Virginia University

    Morgantown, West Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.